Squarepoint Ops LLC lifted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 540.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 124,744 shares of the company's stock after buying an additional 105,268 shares during the quarter. Squarepoint Ops LLC's holdings in Amneal Pharmaceuticals were worth $988,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Nantahala Capital Management LLC grew its position in Amneal Pharmaceuticals by 37.3% in the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock worth $29,031,000 after acquiring an additional 995,586 shares in the last quarter. BlackBarn Capital Partners LP boosted its holdings in Amneal Pharmaceuticals by 18.2% in the fourth quarter. BlackBarn Capital Partners LP now owns 2,850,000 shares of the company's stock worth $22,572,000 after purchasing an additional 438,388 shares in the last quarter. Mariner LLC increased its position in Amneal Pharmaceuticals by 3,749.1% during the fourth quarter. Mariner LLC now owns 424,291 shares of the company's stock worth $3,360,000 after buying an additional 413,268 shares during the last quarter. Bank of America Corp DE raised its holdings in Amneal Pharmaceuticals by 218.8% during the fourth quarter. Bank of America Corp DE now owns 556,881 shares of the company's stock valued at $4,410,000 after buying an additional 382,222 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Amneal Pharmaceuticals during the fourth quarter valued at about $2,946,000. Institutional investors and hedge funds own 31.82% of the company's stock.
Amneal Pharmaceuticals Stock Down 3.2%
NASDAQ:AMRX traded down $0.24 on Wednesday, reaching $7.21. The stock had a trading volume of 1,830,510 shares, compared to its average volume of 1,444,956. The stock has a fifty day moving average price of $7.42 and a 200-day moving average price of $7.97. Amneal Pharmaceuticals, Inc. has a 1-year low of $6.29 and a 1-year high of $9.48. The company has a market capitalization of $2.26 billion, a P/E ratio of -10.60 and a beta of 1.17.
Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. The firm had revenue of $695.42 million for the quarter, compared to analysts' expectations of $714.78 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. Sell-side analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the transaction, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. This trade represents a 9.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 26.56% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on AMRX shares. Wall Street Zen downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Barclays boosted their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $11.50.
Check Out Our Latest Report on Amneal Pharmaceuticals
Amneal Pharmaceuticals Profile
(
Free Report)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
See Also
Before you consider Amneal Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amneal Pharmaceuticals wasn't on the list.
While Amneal Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
